EPT-13RAPIRI I – PHASE I STUDY OF DAILY ORAL RAPAMYCIN AND INTRAVENOUS IRINOTECAN IN CHILDREN WITH A RECURRENT/REFRACTORY MALIGNANT SOLID TUMOR: GOOD TOLERANCE AND PROMISING RESULTS IN BRAIN TUMORS - A REPORT FROM THE SOCIÉTÉ FRANÇAISE DES CANCERS ET L...

  • Sarah Jannier, Veronique Kemmel, Meriam Koob, Françoise Farace, Erwan Pencreach, Birgit Geoerger, Isabelle Aerts, Cecile Faure-Conter, Pierre Leblond, Nicolas Andre, Yves Perel, Nadège Corradini, Anne Isabelle Bertozzi, Natacha Entz-Werlé
  • Neuro-Oncology, June 2016, Oxford University Press (OUP)
  • DOI: 10.1093/neuonc/now069.12

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1093/neuonc/now069.12

The following have contributed to this page: Dr Véronique Kemmel